Myriad Genetics, Inc. Stock price

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
22.91 USD -2.51% Intraday chart for Myriad Genetics, Inc. -2.14% +19.70%
Sales 2023 * 751M Sales 2024 * 821M Capitalization 2.03B
Net income 2023 * -256M Net income 2024 * -90M EV / Sales 2023 * 2.72 x
Net Debt 2023 * 10.18M Net Debt 2024 * 58.98M EV / Sales 2024 * 2.55 x
P/E ratio 2023 *
-7.33 x
P/E ratio 2024 *
-21.3 x
Employees 2,600
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.51%
1 week-2.14%
Current month+7.11%
1 month+12.80%
3 months+31.06%
6 months+29.14%
Current year+19.70%
More quotes
1 week
22.50
Extreme 22.5
23.70
1 month
20.74
Extreme 20.74
23.75
Current year
17.18
Extreme 17.18
23.75
1 year
13.82
Extreme 13.82
24.21
3 years
13.82
Extreme 13.82
36.95
5 years
9.24
Extreme 9.24
48.40
10 years
9.24
Extreme 9.24
50.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 20-08-12
Director of Finance/CFO 49 Jan. 28
Chief Tech/Sci/R&D Officer 44 14-03-31
Members of the board TitleAgeSince
Chairman 65 09-09-15
Director/Board Member 63 22-10-30
Director/Board Member 65 20-05-26
More insiders
Date Price Change Volume
24-02-21 22.91 -2.51% 517,101
24-02-20 23.5 +1.08% 441,598
24-02-16 23.25 -1.44% 329,315
24-02-15 23.59 +0.77% 608,716
24-02-14 23.41 +9.85% 599,342

Delayed Quote Nasdaq, February 21, 2024 at 04:00 pm EST

More quotes
Myriad Genetics, Inc.is a genetic testing and precision medicine company. The Company provides testing that helps assess an individual's risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. It has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
22.91 USD
Average target price
22.5 USD
Spread / Average Target
-1.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Myriad Genetics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer